Tsutsui H, Ando S, Kubota T, Kuroiwa-Matsumoto M, Egashira K, Sasaki M, Kuwabara Y, Koyanagi S, Yasui H, Takeshita A
Research Institute of Angiocardiology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Am J Card Imaging. 1996 Jan;10(1):14-22.
Myocardial uptake of iodine-123 meta-iodobenzylguanidine (123I-MIBG) was measured using scintigrams at rest in 12 patients with isolated, nonischemic mitral regurgitation (MR; regurgitant fraction 64% +/- 7%) and was related to the left ventricular (LV) function assessed by cardiac catheterization. Iodine-123 meta-iodobenzylguanidine activity in the upper mediastinum, liver, and lung was comparable between MR and control (n = 8) patients. The heart-to-mediastinum 123I-MIBG activity ratio 4 hours after injection was significantly (p < 0.01) decreased in MR (2.0 +/- 0.1, mean +/- SE) compared with control (2.7 +/- 0.1) with the increased clearance of MIBG. In addition, MR patients had significantly greater heterogeneity in the 123I-MIBG distribution within the myocardial images (26.1% +/- 2.1% intraimage variability for MR versus 15.6% +/- 0.8% for control, p < 0.01). Myocardial 123I-MIBG activity correlated positively with cardiac index and negatively with pulmonary capillary wedge pressure and LV volume indexes. Thus, 123I-MIBG scintigrams can be a noninvasive method for assessing the contractile dysfunction in MR.
在12例孤立性、非缺血性二尖瓣反流（MR；反流分数64%±7%）患者静息状态下，使用闪烁扫描法测量了碘-123间碘苄胍（123I-MIBG）的心肌摄取情况，并将其与通过心导管检查评估的左心室（LV）功能相关联。MR患者与对照组（n = 8）患者相比，上纵隔、肝脏和肺部的碘-123间碘苄胍活性相当。注射后4小时，MR组（2.0±0.1，均值±标准误）的心-纵隔123I-MIBG活性比值与对照组（2.7±0.1）相比显著降低（p < 0.01），MIBG清除增加。此外，MR患者心肌图像内123I-MIBG分布的异质性显著更高（MR组图像内变异性为26.1%±2.1%，对照组为15.6%±0.8%，p < 0.01）。心肌123I-MIBG活性与心脏指数呈正相关，与肺毛细血管楔压和左心室容积指数呈负相关。因此，123I-MIBG闪烁扫描可作为评估MR患者收缩功能障碍的一种非侵入性方法。
